Ex-microbiologist

[Ex-microbiologist @microbiol_sci]

@GenomicsCow How is that different from what they offer now?

[Ex-microbiologist @microbiol_sci]

@kenbwork What makes you think folks have not done this?
“If you were to build a company just to commercialize vanilla single cell at scale…what would tissue dissociation, viability staining, purification, library prep, analysis, etc. actually look like? ”

[Ex-microbiologist @microbiol_sci]

@kenbwork It is likely worth spending timing talking to CROs about their challenges and cost structure. Growing a physical lab to address a rapidly changing market using many assays is a difficult task. It may waste money to “over” optimize when things change quickly.

[Ex-microbiologist @microbiol_sci]

@OmicsOmicsBlog @GenomicsCow I was thinking along the lines of the comment from @GenomicsCow about microscopy being commoditized compared to NGS. The imaging tech behind sequencers still amazes me

[Ex-microbiologist @microbiol_sci]

@LGMartelotto @GenomicsCow @mehtamanal @hoheyn @OmicsOmicsBlog @MollyminHe Your approach was incredibly clever, and you released the protocol in a way that others can easily replicate. The field will appreciate it so much!

[Ex-microbiologist @microbiol_sci]

@GenomicsCow @mehtamanal @hoheyn @OmicsOmicsBlog @LGMartelotto @MollyminHe An assay isn't a product, but you can't have a product without an assay.
This is incredibly exciting work, but it takes a lot of work to turn something that works to something that works for most people, most of the time. That said, I'm excited to see the future for this tech!

[Ex-microbiologist @microbiol_sci]

@ToumyGG @GenomicsCow @CatharineAquino Isn't that the definition of "funding" though? These all rely on having sufficient funding to build something that meets rapidly changing market needs AND test its commercial viability.

[Ex-microbiologist @microbiol_sci]

@CatharineAquino Making flexible, innovative, and disruptive tools is a seemingly impossible balance between being innovative, getting to market quickly, and building something robust. The grace to balance these often comes down to funding as @GenomicsCow suggests.

[Ex-microbiologist @microbiol_sci]

@KostChristian @markowenmartin @ATinyGreenCell That assumes there is no growth difference, which is pretty reasonable.

[Ex-microbiologist @microbiol_sci]

@CatharineAquino Trying to upgrade all those MiSeqs?

[Ex-microbiologist @microbiol_sci]

@CatharineAquino @RocheSequencing @illumina @agbt They just had a Genome Web article in May saying they’re making “good progress” so maybe AGBT is to soon…

[Ex-microbiologist @microbiol_sci]

@OmicsOmicsBlog Is it just me or is 10x rolling back their presence at many conferences?

[Ex-microbiologist @microbiol_sci]

@GenomicsCow No shade! They make great products. Their library keep products aren’t always best in class for life sciences folks, but great quality.

[Ex-microbiologist @microbiol_sci]

@ATinyGreenCell @dieworkwear @mcmansionhell is the closest I know.

[Ex-microbiologist @microbiol_sci]

@bioinformer @illumina They still aren't that cheap though? What do you think the ASP is?

[Ex-microbiologist @microbiol_sci]

@lpachter That is true art!
My head knows upset plots are better, but they can be difficult to interpret without careful thought. Not every plot can be perfect i suppose.